Dupilumab in atopic dermatitis patients with chronic hepatitis B
Dupilumab in atopic dermatitis patients with chronic hepatitis B
复制标题
Dupilumab 在慢性乙型肝炎特应性皮炎患者中的应用
DOI：
10.1002/cia2.12209
复制
发表时间：
2022
影响因子：
1
通讯作者：
Kanazawa Nobuo
中科院分区：
文献类型：
--
作者：
Matsutani Masako;Imai Yasutomo;Nakatani‐Kusakabe Minori;Natsuaki Masaru;Yamanishi Kiyofumi;Kanazawa Nobuo
慢性B肝炎病毒（HBV）感染是肝硬化和肝细胞癌的主要原因，影响全球3.7亿人。1在免疫抑制药物引起的新发急性肝炎或再激活的HBV感染中也可导致死亡。表1接受dupilumab治疗的特应性皮炎和慢性B型肝炎病毒感染患者的临床特征患者年龄性别血液检测HBV-DNA TaqMan® PCR，Dupilumab给药后，HBs Ag HBs Ab HBc Ab 0 w 4 w 16 w 28 w 40 w 52 w 64 w 76 w 88 w 100 w# 1 59 M−++−# 2 60 F−++− + −# 3 47 M−++ −#4 51 M−+−# 5 60 F−+ −缩写：Ab，抗体; Ag，抗原; F，女性; HBV，B型肝炎病毒; M，男性; w，周（允许±6周的范围;空格表示无数据）。研究方案经兵库医学院伦理审查委员会批准，符合赫尔辛基宣言的伦理指南。
Dear Editor, Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma, affecting 370 million people worldwide. 1 It can also lead to death in de novo acute hepatitis or reactivated HBV infection caused by immunosuppressive drugs. TABLE 1 Clinical characteristics of the patients with atopic dermatitis and chronic hepatitis B virus infection treated with dupilumab Patient Age Gender Blood test HBV-DNA TaqMan® PCR, After dupilumab administration HBs Ag HBs Ab HBc Ab 0 w 4 w 16 w 28 w 40 w 52 w 64 w 76 w 88 w 100 w# 1 59 M−++−−−−−−# 2 60 F−++−−−−−+−−# 3 47 M−++−−−−−# 4 51 M−+−−−−−−−# 5 60 F−+−−−−− Abbreviations: Ab, antibody; Ag, antigen; F, female; HBV, hepatitis B virus; M, male; w, weeks (a range of±6 weeks is allowed; blank spaces indicate no data). The study protocol was approved by the Ethics Review Board of Hyogo College of Medicine and conformed to the ethical guidelines of the Declaration of Helsinki.